ReviewFrontiers in microbiology2026
Huanglian Wendan decoction modulates gut microbiota-brain axis for depression comorbid with insomnia: a mini review.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression comorbid with insomnia (DCI) is a highly prevalent mental disorder with complex pathogenesis, posing great clinical challenges for Western medical interventions due to adverse reactions, drug dependence and single targets. Accumulating preclinical evidence confirms the microbiota-gut-brain axis (MGBA) as a core regulatory hub in DCI pathogenesis, with gut microbiota dysbiosis being the initiating factor that disrupts host neuroendocrine, immune and circadian systems via multiple pathways, forming a vicious circle to aggravate DCI symptoms. Huanglian Wendan Decoction (HLWDD), a classic traditional Chinese medicine herbal formula, shows potential therapeutic effects on DCI by targeting the gut microbiota-the core node of MGBA. Notably, most relevant evidence is derived from animal preclinical models. This Mini Review succinctly summarizes the core pathological mechanisms of gut microbiota dysbiosis inducing DCI via MGBA, and elaborates HLWDD's multi-target therapeutic effects on DCI centered on gut microbiota regulation: reshaping gut microbiota composition, promoting short-chain fatty acids (SCFAs) production, and protecting intestinal mucosal barrier integrity, as well as improving central nervous system dysfunction via MGBA bidirectional regulation. We also discuss the existing academic controversies, critical research gaps and potential future development directions in this field. This review highlights the gut microbiota as a key therapeutic target of HLWDD for DCI, and provides a scientific basis for its clinical application and translational research via MGBA modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.